Physician profile
Aimee Knott
NPI 1801554639
$5,642.12
in general payments reported to CMS, 2019-2025
31 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,351 · 2023: $1,011 · 2024: $1,805 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,183 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,182.53 |
| Education | $109.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,723.19 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $830.97 | 2022-2025 | Xifaxan, Relistor, Trulance |
| Genzyme Corporation | $538.39 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $427.60 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $387.98 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $262.69 | 2024-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $252.86 | 2022-2025 | Dupixent |
| Amgen INC. | $139.35 | 2022-2025 | Uplizna |
| Celgene Corporation | $110.77 | 2022-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $107.28 | 2022 | |
| Janssen Scientific Affairs, LLC | $75.84 | 2025 | |
| Qol Medical, LLC | $73.90 | 2022-2025 | Sucraid |
| Intercept Pharmaceuticals, INC. | $66.59 | 2022-2025 | Ocaliva |
| Gilead Sciences, INC. | $64.43 | 2023-2025 | |
| Ardelyx, INC. | $61.22 | 2024 | Ibsrela |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $60.63 | 2024 | Iqirvo |
| Boston Scientific Corporation | $53.46 | 2022-2024 | Watchman Access System, Watchman Flx |
| Pfizer INC. | $49.49 | 2024-2025 | |
| Daiichi Sankyo INC. | $48.34 | 2022 | |
| Neuraxis, INC. | $47.66 | 2025 | |
| Ironwood Pharmaceuticals, INC | $36.56 | 2022-2024 | |
| Organon LLC | $30.37 | 2022-2025 | Renflexis, Hadlima |
| Tersera Therapeutics LLC | $28.91 | 2023 | Xermelo, Zoladex |
| Lilly USA, LLC | $28.45 | 2025 | Omvoh |
| Celltrion USA INC. | $25.08 | 2023 | Yuflyma |
| Novo Nordisk INC | $24.51 | 2025 | Wegovy |
| Mylan Institutional INC. | $19.99 | 2023 | Hulio |
| Astrazeneca Pharmaceuticals LP | $18.98 | 2023 | Andexxa |
| Pharmacosmos Therapeutics INC. | $16.98 | 2024 | Monoferric |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.24 | 2023 | Cyltezo |
| Fresenius Kabi USA, LLC | $13.41 | 2024 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Knott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.